Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 12Fallopian Tube Neoplasms 8Sarcoma 2Neoplasms 2Neoplasm Metastasis 2Multi-centric Castleman's Disease 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Cancer Recurrent 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphadenopathy 1Liposarcoma 1Leiomyosarcoma 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1HIV Infections 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Mucinous Adenocarcinoma 1Endometrial Neoplasms 1

Interventions

Specimen Handling 3pembrolizumab 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Biopsy 2talimogene laherparepvec 1peposertib 1liposomal doxorubicin 1fludarabine 1aldesleukin 1X-Rays 1Radiotherapy 1Radiation 1Nivolumab 1Ipilimumab 1Histamine H2 Antagonists 1Famotidine 1Cyclophosphamide 1CTLA-4 Antigen 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × liposomal doxorubicin × 30 days × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡